Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities research analysts at Leerink Swann issued their Q1 2018 earnings per share estimates for shares of Vertex Pharmaceuticals in a research report issued on Monday. Leerink Swann analyst G. Porges anticipates that the pharmaceutical company will earn $0.27 per share for the quarter. Leerink Swann also issued estimates for Vertex Pharmaceuticals’ Q2 2018 earnings at $0.26 EPS, Q3 2018 earnings at $0.30 EPS and Q4 2018 earnings at $0.35 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The business had revenue of $578.20 million for the quarter, compared to analysts’ expectations of $522.07 million. During the same quarter last year, the firm earned $0.16 earnings per share. The business’s revenue was up 39.7% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: “Leerink Swann Comments on Vertex Pharmaceuticals Incorporated’s Q1 2018 Earnings (VRTX)” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/22/leerink-swann-comments-on-vertex-pharmaceuticals-incorporateds-q1-2018-earnings-vrtx.html.

Several other equities research analysts have also recently issued reports on VRTX. Cowen and Company restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 1st. BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 19th. Needham & Company LLC restated a “buy” rating and set a $195.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. BMO Capital Markets restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. Finally, DA Davidson assumed coverage on Vertex Pharmaceuticals in a report on Friday, September 29th. They set a “buy” rating and a $200.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-three have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $173.15.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) opened at $145.06 on Wednesday. Vertex Pharmaceuticals has a fifty-two week low of $71.46 and a fifty-two week high of $167.85. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $36,579.86, a price-to-earnings ratio of 241.07, a PEG ratio of 3.67 and a beta of 1.63.

A number of large investors have recently bought and sold shares of VRTX. Dimensional Fund Advisors LP grew its stake in Vertex Pharmaceuticals by 2.1% in the first quarter. Dimensional Fund Advisors LP now owns 272,933 shares of the pharmaceutical company’s stock worth $29,842,000 after purchasing an additional 5,496 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Vertex Pharmaceuticals in the first quarter worth about $4,387,000. Creative Planning grew its stake in Vertex Pharmaceuticals by 32.8% in the second quarter. Creative Planning now owns 3,716 shares of the pharmaceutical company’s stock worth $479,000 after purchasing an additional 917 shares in the last quarter. Fisher Asset Management LLC grew its stake in Vertex Pharmaceuticals by 14.1% in the second quarter. Fisher Asset Management LLC now owns 5,946 shares of the pharmaceutical company’s stock worth $766,000 after purchasing an additional 733 shares in the last quarter. Finally, State of Alaska Department of Revenue acquired a new position in Vertex Pharmaceuticals in the second quarter worth about $197,000. Institutional investors and hedge funds own 92.42% of the company’s stock.

In other news, EVP David Altshuler sold 1,796 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $160.00, for a total transaction of $287,360.00. Following the sale, the executive vice president now directly owns 107,807 shares of the company’s stock, valued at $17,249,120. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Stuart A. Arbuckle sold 6,290 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, October 27th. The stock was sold at an average price of $143.97, for a total value of $905,571.30. Following the sale, the executive vice president now directly owns 116,952 shares in the company, valued at $16,837,579.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 220,315 shares of company stock worth $32,107,270. Corporate insiders own 1.80% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Earnings History and Estimates for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.